| MYC deregulation in primary human cancers M Kalkat, J De Melo, KA Hickman, C Lourenco, C Redel, D Resetca, ... Genes 8 (6), 151, 2017 | 390 | 2017 |
| PKM2, a central point of regulation in cancer metabolism N Wong, J De Melo, D Tang International journal of cell biology 2013 (1), 242513, 2013 | 265 | 2013 |
| Aldehyde dehydrogenase 3A1 associates with prostate tumorigenesis J Yan, J De Melo, JC Cutz, T Aziz, D Tang British journal of cancer 110 (10), 2593-2603, 2014 | 74 | 2014 |
| PTEN inhibits BMI1 function independently of its phosphatase activity C Fan, L He, A Kapoor, AP Rybak, J De Melo, JC Cutz, D Tang Molecular cancer 8, 1-14, 2009 | 72 | 2009 |
| MYC dephosphorylation by the PP1/PNUTS phosphatase complex regulates chromatin binding and protein stability D Dingar, WB Tu, D Resetca, C Lourenco, A Tamachi, J De Melo, ... Nature communications 9 (1), 3502, 2018 | 54 | 2018 |
| Neural cell adhesion protein CNTN1 promotes the metastatic progression of prostate cancer J Yan, D Ojo, A Kapoor, X Lin, JH Pinthus, T Aziz, TA Bismar, F Wei, ... Cancer research 76 (6), 1603-1614, 2016 | 51 | 2016 |
| Changes in PKM2 associate with prostate cancer progression N Wong, J Yan, D Ojo, J De Melo, JC Cutz, D Tang Cancer investigation 32 (7), 330-338, 2014 | 47 | 2014 |
| Elevation of SIPL1 (SHARPIN) increases breast cancer risk J De Melo, D Tang PloS one 10 (5), e0127546, 2015 | 37 | 2015 |
| Upregulation of FAM84B during prostate cancer progression N Wong, Y Gu, A Kapoor, X Lin, D Ojo, F Wei, J Yan, J de Melo, P Major, ... Oncotarget 8 (12), 19218, 2017 | 28 | 2017 |
| Modelling the MYC-driven normal-to-tumour switch in breast cancer C Lourenco, M Kalkat, KE Houlahan, J De Melo, J Longo, SJ Done, ... Disease models & mechanisms 12 (7), dmm038083, 2019 | 23 | 2019 |
| SIPL1-facilitated PTEN ubiquitination contributes to its association with PTEN J De Melo, X Lin, L He, F Wei, P Major, D Tang Cellular Signalling 26 (12), 2749-2756, 2014 | 22 | 2014 |
| Biphasic alteration of butyrylcholinesterase (BChE) during prostate cancer development Y Gu, MJ Chow, A Kapoor, W Mei, Y Jiang, J Yan, J De Melo, M Seliman, ... Translational oncology 11 (4), 1012-1022, 2018 | 21 | 2018 |
| Common reduction of the Raf kinase inhibitory protein in clear cell renal cell carcinoma B Hill, J De Melo, J Yan, A Kapoor, L He, JC Cutz, X Feng, N Bakhtyar, ... Oncotarget 5 (17), 7406, 2014 | 18 | 2014 |
| CYB5D2 displays tumor suppression activities towards cervical cancer Y Xie, YT Shen, A Kapoor, D Ojo, F Wei, J De Melo, X Lin, N Wong, J Yan, ... Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1862 (4), 556-565, 2016 | 13 | 2016 |
| SIPL1 enhances the proliferation, attachment, and migration of CHO cells by inhibiting PTEN function J De Melo, V Wu, L He, J Yan, D Tang International journal of molecular medicine 34 (3), 835-841, 2014 | 13 | 2014 |
| The protein-protein interaction-mediated inactivation of PTEN J De Melo, L He, D Tang Current molecular medicine 14 (1), 22-33, 2014 | 12 | 2014 |
| Lysine-52 stabilizes the MYC oncoprotein through an SCFFbxw7-independent mechanism J De Melo, SS Kim, C Lourenco, LZ Penn Oncogene 36 (49), 6815-6822, 2017 | 10 | 2017 |
| Dataset on the effects of CYB5D2 on the distribution of HeLa cervical cancer cell cycle Y Xie, YT Shen, A Kapoor, D Ojo, F Wei, J De Melo, X Lin, N Wong, J Yan, ... Data in brief 6, 811-816, 2016 | 5 | 2016 |
| Image‐Based Analysis of Protein Stability KA Hickman, S Hariharan, J De Melo, J Ylanko, LC Lustig, LZ Penn, ... Cytometry Part A 97 (4), 363-377, 2020 | 3 | 2020 |
| Modeling the MYC-driven normal-to-tumour switch in breast cancer C Lourenco, M Kalkat, KE Houlahan, JD Melo, J Longo, SJ Done, ... bioRxiv, 380931, 2018 | 1 | 2018 |
Damu TangDepartment of Surgery, McMaster University在 mcmaster.ca 的电子邮件经过验证
